Luna Health has completed a Series A funding round, raising $23.6m to propel the advancement of the Luna insulin patch pump.

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Viking Therapeutics reports positive top-line results from phase 2 VENTURE-Oral Dosing trial of VK2735 tablet formulation in patients with obesity: San Diego Wednesday, August 20, ...

Shares in Viking Therapeutics have lost more than 40% of their value after it reported phase 2 results that showed that its ...

The trial’s first part will test single ascending doses, while the second will focus on multiple ascending doses of the ...

TGTX is also now in the clinic with its CAR-T therapy it is developing for multiple sclerosis, although a competitor readout ...